Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Lancet Haematol. 2020 Sep 5;7(10):e724–e736. doi: 10.1016/S2352-3026(20)30210-6

Fig. 1.

Fig. 1

Trial profile.

Sixteen patients with high risk or relapsed/refractory myelodysplastic syndrome were enrolled on this trial and their outcomes will be reported separately. CR = complete remission, CRi = CR with incomplete hematologic recovery, MLFS = morphologic leukemia-free state.